Swiss drugmaker Novartis posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag.» Read More
As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.
CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.
Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.
European shares closed lower on Tuesday, as Ukraine worries and fears about slowing demand in China weighed on stocks.
Swiss pharmaceuticals company Roche posted a rise in first-quarter sales but failed to meet market expectations as a strong Swiss franc hit results.
Severin Schwan, CEO of Roche, says he is "pleased" with the share price and results reported by the company.
The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.
An upbeat handover from Wall Street on Thursday inspired gains in most Asian shares on Friday.
Sunday's vote in Switzerland has raised fears that the measure is the latest in a long list of reforms that could curb the country's business-friendly environment.
Swiss voters on Sunday narrowly backed proposals to reintroduce immigration quotas with the European Union, Swiss television reported.
Global healthcare company Roche is confident of growth in emerging markets despite the economic slowdown.
But the delay in packaging the liquid version has not affected supplies of regular Tamiflu, said the Roche unit that makes the medication.
European equities closed lower on Tuesday as investors remained cautious over the timing of the Fed's reduction of its stimulus program.
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
European equities closed narrowly higher on Thursday, with investors underwhelmed by U.S. lawmakers finally reaching a deal to lift the country's borrowing limit.
Emerging markets still offer room for growth, Roche's CEO told CNBC after the pharma posted an 8 percent increase in third-quarter sales.
With Washington's debt battle over, markets will quickly shift focus to earnings and how much the government shutdown actually impacted the economy.